On July 25, 2022 MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported that the Company will release its financial results for the second quarter of 2022 after the market closes on Monday, August 8, 2022 (Press release, MacroGenics, JUL 25, 2022, View Source [SID1234616905]). MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Monday, August 8, 2022, at 4:30 pm ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information

To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company’s website at View Source A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.

On July 25, 2022 Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), a company developing new approaches for the treatment of cancer and fibrosis, reported that an abstract describing the Company’s ACCENT clinical trial of AMP945 in first-line patients with advanced pancreatic cancer has been accepted for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Special Conference on Pancreatic Cancer, being held from September 13-16 in Boston, MA (Press release, Amplia Therapeutics, JUL 25, 2022, View Source;[email protected] [SID1234616890]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be entitled "Rationale for the use of pulsed rather than continual dosing of the novel Focal Adhesion Kinase inhibitor AMP945 in pancreatic cancer" and will describe the scientific rationale and clinical trial design for ACCENT. The trial is currently open for recruitment and has been registered on ClinialTrials.gov with an identifier number of NCT05355298.

"The AACR (Free AACR Whitepaper) special topic meetings attract the world’s leading cancer researchers who are working at the cutting edge of cancer research and new drug development. We’re delighted to have Amplia’s work accepted for presentation in this forum and expect it will raise awareness in the global clinical community of AMP945 and its potential in this devastating cancer."

This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics.

On July 25, 2022 OPKO Health, Inc. (NASDAQ: OPK) reported that operating and financial results for the three and six months ended June 30, 2022 after the close of the U.S. financial markets on Thursday, August 4, 2022 (Press release, Opko Health, JUL 25, 2022, View Source [SID1234616906]). OPKO’s senior management will provide a business update and discuss financial results as well as financial guidance during a conference call and live audio webcast on August 4th beginning at 4:30 p.m. Eastern time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CONFERENCE CALL & WEBCAST INFORMATION

OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will be given a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing (833) 630-0584 (U.S.) or (412) 317-1815 (International). A webcast of the call may also be accessed at OPKO’s Investor Relations page and here.

A telephone replay will be available until August 11, 2022 by dialing (877) 344-7529 (U.S.) or (412) 317-0088 (International) and providing the passcode 5775821. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here.

On July 25, 2022 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, reported that the Company expects to report financial and business results for the second quarter of 2022 after the market closes on Thursday, August 4, 2022 (Press release, Supernus, JUL 25, 2022, View Source [SID1234616907]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the second quarter 2022 financial and business results on Thursday, August 4, 2022 at 4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.

A live webcast will be accessible in the Events & Presentation section of the Company’s Investor Relations website www.supernus.com/investors.

Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.

Following the live call, a replay will be available on the Company’s Investor Relations website www.supernus.com/investors. The webcast will be available on the Company’s website for 60 days following the live call.

On July 25, 2022 Technophage, together with partners LX Bio, VectorB2B and FFUL reported the signing of a new PRR Grant Agreement with the Portuguese Government, in the scope of the Mobilizing Agendas for Business Innovation in Portugal (Press release, TechnoPhage, JUL 25, 2022, View Source;utm_medium=rss&utm_campaign=technophage-announces-signing-of-a-prr-grant-agreement-with-the-portuguese-government [SID1234616925]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Bio-Hub consortium aims to expand the development of biological medicines, conduct clinical trials of late phases, and implement registrations, marketing and distribution of these drugs globally. This strategy will increase the volume of exports of value-added products and increase highly qualified employment. The starting point will be the creation of a large-scale plant for the production of biological medicines with GMP-certified dedicated spaces that will reinforce the development of innovative medicines in the country, while supporting the needs of national start-ups.

"This new consortium will be life-changing for the companies and partners involved, constituting an exciting milestone for the whole team" commented Miguel Garcia, CEO of TechnoPhage.

The project will take place over a period of 36 months and aims to produce new knowledge in the R&D of biological medicines, a health market with a strong prospect of growth in the next decade.